Finally, John Hambor will extend CTG’s offering into the exciting arena of cell-based and tissue engineering technologies as tools for drug discovery, screening, and toxicology testing. “John brings not only scientific breadth and depth to the firm but he has the ability to leverage his successful career in the pharmaceutical industry in the strategic commercialization of cell-based technologies,” says Sarah Haecker, who has previously collaborated with Hambor.
“John brings to CTG and its clients his broad perspective of utilizing stem cell technologies across the entire drug discovery process. With a deep understanding of regenerative medicine, cell therapy, tissue engineering, and classic pharmaceutical drug development, he provides his clients with a unique combination of technical and business knowledge for business development, strategic planning, product development, market analysis, licensing, patent protection of intellectual property, and partnering & coalition building.”
Prior to joining CTG, Sarah was an independent business strategist in the Regenerative Medicine Industry. With more than 16 years of senior-level management experience she uniquely combines technical and business knowledge with emphasis in strategy, business development, licensing, opportunity assessment, market analysis and partnering early to late stage technologies in
Copyright©2010 Vocus, Inc.
All rights reserved